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Community-acquired C. difﬁcile infection
(CA-CDI)
S U M M A R Y
Clostridium difﬁcile is the most important cause of nosocomial diarrhea, mainly associated with antibiotic
use and immunodeﬁciency. Although, an increased incidence of community-acquired C. difﬁcile infection
(CA-CDI) has been reported worldwide, this infection has been under-diagnosed in Latin America. This is
the ﬁrst report of a CA-CDI case in Latin America, in an HIV-positive patient with cancer.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Clostridium difﬁcile is recognized as the main cause of diarrhea
and pseudomembranous colitis in hospitalized patients. Risk
factors for the development of C. difﬁcile infection (CDI) include
advanced age, hospitalization, and severe illness. Cancer patients
and HIV-infected patients have immunological failures that
predispose them to CDI. These patients are at risk of CDI,
independent of antibiotic or healthcare facility exposure, because
of their clinical condition and the use of chemotherapeutic agents,
which usually affect the immune system.1
In Brazil, research into the incidence of C. difﬁcile is still scarce,
although studies carried out in hospitals in Rio de Janeiro, Sa˜o
Paulo, and Porto Alegre (southern and southeastern regions) have
reported high and increasing incidences compared to European* Corresponding author.
E-mail address: cecilialcosta@hotmail.com (C.L. Costa).
http://dx.doi.org/10.1016/j.ijid.2014.06.010
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).and Costa Rican hospitals, with the occurrence of complicated
cases of CDI and deaths resulting from severe infection.2 However,
community-acquired CDI (CA-CDI) infection has been under-
diagnosed. This is the ﬁrst report of a CA-CDI case in an HIV-
positive patient with cancer in Latin America, pointing to the
importance of investigating this pathogen in community-acquired
diarrhea in developing countries, especially among patients with
an immunodeﬁciency.
2. Case report
A 68-year-old woman who was HIV-positive was admitted to a
cancer reference hospital in northeastern Brazil in May 2013. She
presented with clinical symptoms of diarrhea, which had lasted for
6 days. She had been diagnosed with rectal cancer in early 2012. In
December 2012, she underwent rectosigmoidectomy and abdomi-
nal lymphadenectomy. She was on adjuvant chemotherapy
(regimen of folinic acid, 5-ﬂuorouracil, and oxaliplatin), having
received the ﬁrst cycle in March 2013. She had not used antibioticsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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carried out, as per the protocol for all patients who hold risk factors
and suffer from diarrhea.
Analysis of a diarrhea stool sample collected on the third day of
hospitalization revealed the presence of C. difﬁcile toxin A/B
(ProSpecT Clostridium difﬁcile Toxin A/B Microplate, Remel).
Alcohol shock was performed on the stool sample, followed by
culture on cefoxitin–cycloserine–fructose agar (CCFA, Oxoid) and
fastidious anaerobe broth (FAB) for 5 and 15 days, respectively,
incubated under anaerobic conditions (anaerobic jar 90% N2, 10%
CO2). Then the FAB was inoculated onto another CCFA. Character-
istic C. difﬁcile colonies on CCFA appeared yellowish, with a
ground-glass appearance; they were circular with slightly
ﬁlamentous edges and ﬂat to low with a rounded elevation. The
colonies were lipase- and lecithinase-negative. These colonies
were inoculated onto Brucella agar with 5% lysed sheep blood and
vitamin K (5 mg/ml) for identiﬁcation and molecular tests.
The identiﬁcation was conﬁrmed by testing with a RapID ANA II
system (Remel) and by tpi gene PCR ampliﬁcation.3
The ampliﬁcation results for tcdA and tcdB gene fragments of
PaLoc (Pathogenicity locus) were positive, while the results for the
binary toxin gene cdtB and evidence of deletion of the putative
regulatory gene tcdC were negative, using a previously reported
method.3 Molecular strain typing was conducted using pulsed-
ﬁeld gel electrophoresis (PFGE), as described previously, using
SmaI genomic DNA digestion.3 DNA fragment patterns were
compared to the database of the National Microbiology Laboratory,
Canada, using BioNumerics v. 4.6 software (Applied Maths); the
isolate was typed as NAP4.
Antibiotic susceptibility was determined by Etest on Brucella
agar with 5% sheep blood and vitamin K (5 mg/ml). The isolate was
resistant to azithromycin (>256 mg/ml), ciproﬂoxacin (25 mg/ml),
tetracycline (128 mg/ml), and cefotaxime (>32 mg/ml), but sus-
ceptible to clindamycin (0.125 mg/ml), ceftriaxone (1.5 mg/ml),
metronidazole (0.025 mg/ml), chloramphenicol (3 mg/ml), rifam-
pin (<0.002 mg/ml), levoﬂoxacin (4 mg/ml), moxiﬂoxacin (1.5 mg/
ml), and vancomycin (0.5 mg/ml).
Laboratory studies showed a low leukocyte count (1.462  109/
l; neutrophils 0.520  109/l and lymphocytes 0.340  109/l),
hemoglobin (7.5 g/dl), and platelets (108  109/l). Intestinal
parasites (protozoa and helminths) and the main gastrointestinal
viruses and bacterial enteric pathogens were not detected in the
stool sample. In accordance with the clinical and laboratory
ﬁndings, the woman was diagnosed with CA-CDI.
The diarrhea ceased approximately a week after the beginning
of metronidazole treatment (40 mg/kg/day for 14 days) and
commercial probiotic therapy.
3. Discussion
Little information is available on the risk factors for CA-CDI.
Some cases have been associated with antibiotic treatment, while
others lack this risk factor. In the case reported here, despite the
absence of hospitalization and use of antibiotics in the last 4
months, the woman presented several risk factors that led her to
develop C. difﬁcile-associated disease, such as age, immunosup-
pression, and co-morbidities (cancer and HIV positivity), in
addition to the use of antineoplastic drugs. Chemotherapeutic
agents such as 5-ﬂuorouracil may induce intestinal mucositis
associated with severe inﬂammatory changes in the colonic
mucosa. Colonic inﬂammation can cause intestinal necrosis, which
promotes an anaerobic environment for C. difﬁcile organisms.1
CDI may account for 10% to 50% of diarrhea among hospitalized
HIV-seropositive patients, and recent evidence suggests that
C. difﬁcile has become the most important pathogen causing
bacterial diarrhea in HIV-seropositive patients in the USA,suggesting that these patients are at increased risk because of
their underlying immunosuppression, exposure to antimicrobials,
exposure to healthcare settings, or a combination of these
factors.2,4
HIV-seropositive individuals, particularly those with lower CD4
counts, are at increased risk of bacterial enteric infection, including
by Escherichia coli, Salmonella spp, and Campylobacter spp.4
However, in this case there was no infection by other pathogens.
The isolated strain did not show high resistance to antibiotics, a
ﬁnding in accordance with community-acquired cases, which
often occur without exposure to antibiotics and comprise about
20% to 22% of CDI cases.5
The isolated NAP4 strain was toxigenic (tcdA and tcdB gene
fragments of the PaLoc were positive), which explains the
symptoms of diarrhea. NAP4 has been a common cause of
healthcare-associated CDI, although it has become less common
in recent years. NAP4 strains have been isolated from cattle and
dogs. These could be considered possible sources for the woman’s
infection. Although food contamination by C. difﬁcile has not been
investigated in Brazil, increasing rates of CDI have raised questions
about the origins of new human strains, sources of human C.
difﬁcile acquisition, and risk factors for the development of
infection.5
Additional studies in the ﬁeld of molecular epidemiology and
the sources of strains causing CA-CDI will advance understanding
of the evolving epidemiology of human CDI and could help in the
development of new strategies to prevent it.
To our knowledge, this is the ﬁrst report of a documented case
of community-acquired C. difﬁcile-induced disease associated with
HIV and cancer in Latin America. The existence of a reservoir of C.
difﬁcile outside the hospital environment is a situation that should
be of concern for individuals who are HIV-positive and/or suffer
from cancer. Public health authorities and scientists should
consider CDI as an emerging infection in the community in these
patients.
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